Christopher K. McLeod

Managing Partner at Elm Street VenturesBoard of Directors

Most recently, Chris was CEO of AxioMx, a portfolio company sold to Abcam Plc in 2015. Throughout his career, he has demonstrated expertise in growing companies through strategic collaborations, innovative marketing, and new product development. Chris served as President and CEO of 454 Life Sciences from February 2005 through September 2011, and managed the integration with Roche Diagnostics following its acquisition in 2007. Previously, he served as Executive Vice President of CuraGen from November 1999, where he oversaw bioinformatics, strategic business development, and collaborative research. Prior to joining CuraGen, Chris spent over two years as CEO of Havas Interactive (formerly Cendant Software), a leading international software developer.